Testing effectiveness (Phase 2)Study completedNCT03192202What this trial is testingAFM13 in Relapsed/Refractory Cutaneous LymphomasWho this might be right forLymphoma, T-Cell, Cutaneous Ahmed Sawas 18
Testing effectiveness (Phase 2)WithdrawnNCT00387530What this trial is testingPhenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive CancerWho this might be right forGastric CancerHead and Neck CancerLymphoma+1 more University of California, San Diego
Testing effectiveness (Phase 2)Study completedNCT01431209What this trial is testingRuxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell TransplantWho this might be right forRecurrent Diffuse Large B-Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma+1 more University of Nebraska 71
Testing effectiveness (Phase 2)UnknownNCT04405375What this trial is testingGPED Regimen for Relapsed/Refractory or Advanced ENKTCLWho this might be right forExtranodal NK/T-cell Lymphoma, Nasal Type Beijing Tongren Hospital 29
Early research (Phase 1)Study completedNCT01689220What this trial is testingSP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in KoreaWho this might be right forPeripheral T-cell Lymphoma Solasia Pharma K.K. 6
Testing effectiveness (Phase 2)Study completedNCT02676778What this trial is testingStudy of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaWho this might be right forPeripheral T-cell LymphomaCutaneous T-cell Lymphoma Eisai Co., Ltd. 45
Early research (Phase 1)Ended earlyNCT02978235What this trial is testingA Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or LymphomaWho this might be right forMultiple MyelomaNonHodgkin Lymphoma Taiho Oncology, Inc. 11
Not applicableStudy completedNCT03098589What this trial is testingRevlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)Who this might be right forLymphoma Celgene 1,149
Testing effectiveness (Phase 2)Ended earlyNCT00082017What this trial is testingUCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell LymphomasWho this might be right forLymphoma, Large-Cell, Ki-1Lymphoma, T-Cell National Cancer Institute (NCI) 20
Early research (Phase 1)Temporarily pausedNCT07388563What this trial is testingAzacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaWho this might be right forLymphoma, T Cell, PeripheralT-cell LymphomaAngioimmunoblastic T-cell Lymphoma+3 more National Cancer Institute (NCI) 20
Very early researchUnknownNCT04028440What this trial is testingΓδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Who this might be right forNon-Hodgkin's LymphomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaChronic Lymphoblastic Leukemia+1 more Institute of Hematology & Blood Diseases Hospital, China 6
Testing effectiveness (Phase 2)UnknownNCT01016990What this trial is testingValproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic LeukemiaWho this might be right forLeukemiaLymphoma Auxilio Mutuo Cancer Center 52
Not applicableStudy completedNCT00049465What this trial is testingStandard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for CancerWho this might be right forCancer Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00436618What this trial is testingEverolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentWho this might be right forLeukemiaLymphomaLymphoproliferative Disorder Mayo Clinic 277
Very early researchNot Yet RecruitingNCT07213882What this trial is testingA Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)Who this might be right forCutaneous T Cell Lymphoma (CTCL)Mycosis FungoidesSezary Syndrome Assistance Publique - Hôpitaux de Paris 30
Testing effectiveness (Phase 2)Ended earlyNCT00972842What this trial is testingLenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)Who this might be right forPeripheral T-Cell Non-Hodgkin's Lymphoma Arbeitsgemeinschaft medikamentoese Tumortherapie 20
Early research (Phase 1)Ended earlyNCT00671112What this trial is testingEverolimus and Bortezomib in Treating Patients With Relapsed or Refractory LymphomaWho this might be right for714leukemiaLymphoma Brian Hill, MD, PhD 30
Early research (Phase 1)Study completedNCT01164709What this trial is testingNelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerWho this might be right forLeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more Swiss Cancer Institute 18
Early research (Phase 1)Study completedNCT05225584What this trial is testingSafety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsWho this might be right forNon Hodgkin Lymphoma (NHL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-Cell Lymphoma (CTCL)+3 more Kymera Therapeutics, Inc. 56
Early research (Phase 1)Study completedNCT02567656What this trial is testingSafety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell LymphomaWho this might be right forLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous Rhizen Pharmaceuticals SA 58